Lacristat
LacriStat.AI is an ophthalmic technology company focused on transforming the diagnosis and treatment of dry eye disease. They leverage AI, nano-fluidics, microelectronics, and advanced technologies to develop real-time, closed-loop solutions. Their mission is to improve patient outcomes by providing personalized treatment plans based on continuous monitoring of tear biomarkers. The company was founded by a team with backgrounds from Google, Verily, and Twenty/Twenty Therapeutics, and is led by CEO Dimitri Azar, MD, MBA. Their approach integrates cutting-edge technology with a deep understanding of ophthalmology to address unmet clinical needs in dry eye care.
Lacristat
LacriStat.AI is an ophthalmic technology company focused on transforming the diagnosis and treatment of dry eye disease. They leverage AI, nano-fluidics, microelectronics, and advanced technologies to develop real-time, closed-loop solutions. Their mission is to improve patient outcomes by providing personalized treatment plans based on continuous monitoring of tear biomarkers. The company was founded by a team with backgrounds from Google, Verily, and Twenty/Twenty Therapeutics, and is led by CEO Dimitri Azar, MD, MBA. Their approach integrates cutting-edge technology with a deep understanding of ophthalmology to address unmet clinical needs in dry eye care.